No Data
No Data
Individual Investors Who Hold 38% of Antengene Corporation Limited (HKG:6996) Gained 77%, Insiders Profited as Well
Antengene Grants Over 15 Million Share Options Under Its 2020 Equity Incentive Plan
D.J. Pharmaceuticals - B (06996) granted 15.22 million share purchase rights.
Dachi Pharmaceutical-B (06996) announced that on October 2, 2024, the company granted... to 77 grantees.
ANTENGENE-B: 2024 INTERIM REPORT
Thailand Approves Antengene's New Drug Application for Multiple Myeloma Drug
Deqi Pharmaceuticals-B (06996.HK): Applications for the marketing approval of two new drugs for different indications of Xiwio have been approved by the Thai Food and Drug Administration.
Gelonghui September 23rd | Deqi Pharmaceutical-B (06996.HK) announced that the Thai Food and Drug Administration has approved the new drug application (NDA) for Xyvio (selinexor tablets) for two indications: (1) in combination with bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy; and (2) in combination with dexamethasone, for the treatment of MM patients who have received at least four prior therapies, including resistance to at least two proteasome inhibitors, two immunomodulators, and one anti-CD38 monoclonal antibody and whose disease has worsened in the last treatment.
No Data
No Data